Fig. 2: Neurocognitive performance in every treatment condition. | Neuropsychopharmacology

Fig. 2: Neurocognitive performance in every treatment condition.

From: Safety and cognitive pharmacodynamics following dose escalations with 3-methylmethcathinone (3-MMC): a first in human, designer drug study

Fig. 2

Panel A shows mean (SE) performances at the DSST (correct substitutions), CTT (lambda-c), DAT (tracking error) and SST (commission errors) as a function of time after dosing. Panel B shows mean (SE) performance at the SMT (immediate and delayed relocation) and MFFT (impulsivity, efficiency). A * denotes a significant (p < 0.05) contrast between 3-MMC and placebo across all time points, with the color of the * representing the 3-MMC dose level.

Back to article page